{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:43:55Z","timestamp":1778798635218,"version":"3.51.4"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:p>BACKGROUND. In 1999, a previous rotavirus vaccine (RotaShield; Wyeth Laboratories, Marietta, PA) was withdrawn from the US market after postlicensure monitoring identified an association with intussusception. Although the new rotavirus vaccine (RotaTeq; Merck, West Point, PA) introduced in 2006 was not associated with intussusception in prelicensure trials, additional monitoring is important to ensure a complete safety profile.<\/jats:p>\n               <jats:p>METHODS. We assessed intussusception reports after RotaTeq vaccination by using data from the Vaccine Adverse Event Reporting System and the Vaccine Safety Datalink, a cohort of children enrolled in managed care. Observed versus expected rate ratios were determined by using vaccine dose distribution data and Vaccine Safety Datalink background intussusception rates.<\/jats:p>\n               <jats:p>RESULTS. Between February 1, 2006, and September 25, 2007, the Vaccine Adverse Event Reporting System received 160 intussusception reports after RotaTeq vaccination. With the assumptions that reporting completeness was 75% and that 75% of the distributed doses of RotaTeq were administered, the observed versus expected rate ratios were 0.53 and 0.91 for the 1\u201321 and 1\u20137 day interval after vaccination, respectively. In the Vaccine Safety Datalink, 3 intussusception cases occurred within 30 days after 111521 RotaTeq vaccinations, compared with 6 cases after 186722 non\u2013RotaTeq vaccinations during the same period. If, like RotaShield, RotaTeq had a 37-fold increased risk of intussusception within 3 to 7 days after vaccination, then 8 intussusception cases would be expected within 3 to 7 days among the \u223c84000 infants vaccinated with the first dose of RotaTeq in the Vaccine Safety Datalink (N = 49902) and the prelicensure trial (N = 34035) combined, whereas no cases have been observed.<\/jats:p>\n               <jats:p>CONCLUSIONS. Available data do not indicate that RotaTeq is associated with intussusception. Although an intussusception risk similar in magnitude to that of RotaShield can be excluded, continued monitoring is necessary for complete assessment of the safety profile of RotaTeq.<\/jats:p>","DOI":"10.1542\/peds.2007-3793","type":"journal-article","created":{"date-parts":[[2008,6,2]],"date-time":"2008-06-02T14:15:50Z","timestamp":1212416150000},"page":"1206-1212","source":"Crossref","is-referenced-by-count":101,"title":["Postlicensure Monitoring of Intussusception After RotaTeq Vaccination in the United States, February 1, 2006, to September 25, 2007"],"prefix":"10.1542","volume":"121","author":[{"given":"Penina","family":"Haber","sequence":"first","affiliation":[{"name":"Immunization Safety Office, Office of the Chief Science Officer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[{"name":"National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector S.","family":"Izurieta","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Baggs","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Office of the Chief Science Officer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gargiullo","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Office of the Chief Science Officer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Office of the Chief Science Officer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Cortese","sequence":"additional","affiliation":[{"name":"National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Miles","family":"Braun","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Belongia","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Foundation, Epidemiology Research Center, Marshfield, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Miller","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Office of the Chief Science Officer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ball","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Iskander","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Office of the Chief Science Officer"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh D.","family":"Parashar","sequence":"additional","affiliation":[{"name":"National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2008,6,1]]},"reference":[{"key":"2021120905433429500_R1","unstructured":"Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082006;55(RR-12):1\u201313"},{"key":"2021120905433429500_R2","doi-asserted-by":"crossref","unstructured":"Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med.\u20082001;344(8):564\u2013572","DOI":"10.1056\/NEJM200102223440804"},{"key":"2021120905433429500_R3","doi-asserted-by":"crossref","unstructured":"Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J.\u20082001;20(4):410\u2013416","DOI":"10.1097\/00006454-200104000-00008"},{"key":"2021120905433429500_R4","unstructured":"Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine: United States, 1998\u20131999. MMWR Morb Mortal Wkly Rep.\u20081999;48(27):577\u2013581"},{"key":"2021120905433429500_R5","doi-asserted-by":"crossref","unstructured":"Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med.\u20082006;354(1):23\u201333","DOI":"10.1056\/NEJMoa052664"},{"key":"2021120905433429500_R6","doi-asserted-by":"crossref","unstructured":"Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology.\u20082005;16(3):336\u2013341","DOI":"10.1097\/01.ede.0000155506.05636.a4"},{"key":"2021120905433429500_R7","unstructured":"Chen RT, DeStefano F, Davis RL, et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ.\u20082000;78(2):186\u2013194"},{"key":"2021120905433429500_R8","doi-asserted-by":"crossref","unstructured":"Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system: VAERS Working Group. Vaccine.\u20081999;17(22):2908\u20132917","DOI":"10.1016\/S0264-410X(99)00132-2"},{"key":"2021120905433429500_R9","doi-asserted-by":"crossref","unstructured":"Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J.\u20082004;23(4):287\u2013294","DOI":"10.1097\/00006454-200404000-00002"},{"key":"2021120905433429500_R10","doi-asserted-by":"crossref","unstructured":"Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting System (VAERS) in monitoring vaccine safety. Pediatr Ann.\u20082004;33(9):599\u2013606","DOI":"10.3928\/0090-4481-20040901-11"},{"key":"2021120905433429500_R11","doi-asserted-by":"crossref","unstructured":"Bines JE, Kohl KS, Forster J, et al. Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine.\u20082004;22(5\u20136):569\u2013574","DOI":"10.1016\/j.vaccine.2003.09.016"},{"key":"2021120905433429500_R12","unstructured":"Food and Drug Administration. FDA public health notification, February 13, 2007: information on RotaTeq and intussusception. Available at: www.fda.gov\/cber\/safety\/phnrota021307.htm. Accessed July 27, 2007"},{"key":"2021120905433429500_R13","unstructured":"Centers for Disease Control and Prevention. Postmarketing monitoring of intussusception after RotaTeq vaccination: United States, February 1, 2006\u2013February 15, 2007. MMWR Morb Mortal Wkly Rep.\u20082007;56(10):218\u2013222"},{"key":"2021120905433429500_R14","doi-asserted-by":"crossref","unstructured":"Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health.\u20081995;85(12):1706\u20131709","DOI":"10.2105\/AJPH.85.12.1706"},{"key":"2021120905433429500_R15","doi-asserted-by":"crossref","unstructured":"Kempe A, Daley MF, Parashar UD, et al. Will pediatricians adopt the new rotavirus vaccine?Pediatrics.\u20082007;119(1):1\u201310","DOI":"10.1542\/peds.2006-1874"},{"key":"2021120905433429500_R16","doi-asserted-by":"crossref","unstructured":"Verstraeten T, Baughman AL, Cadwell B, Zanardi L, Haber P, Chen RT. Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. Am J Epidemiol.\u20082001;154(11):1006\u20131012","DOI":"10.1093\/aje\/154.11.1006"},{"key":"2021120905433429500_R17","doi-asserted-by":"crossref","unstructured":"Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M. Intussusception among recipients of rotavirus vaccine: reports to the Vaccine Adverse Event Reporting System. Pediatrics.\u20082001;107(6). Available at: www.pediatrics.org\/cgi\/content\/full\/107\/6\/e97","DOI":"10.1542\/peds.107.6.e97"},{"key":"2021120905433429500_R18","unstructured":"Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep.\u20081999;48(43):1007"},{"key":"2021120905433429500_R19","doi-asserted-by":"crossref","unstructured":"Santoli JM, Rodewald LE, Maes EF, Battaglia MP, Coronado VG. Vaccines for Children program, United States, 1997. Pediatrics.\u20081999;104(2). Available at: www.pediatrics.org\/cgi\/content\/full\/104\/2\/e15","DOI":"10.1542\/peds.104.2.e15"},{"key":"2021120905433429500_R20","doi-asserted-by":"crossref","unstructured":"Smith PJ, Schwartz B, Mokdad A, Bloch AB, McCauley M, Murphy TV. The first oral rotavirus vaccine, 1998\u20131999: estimates of uptake from the National Immunization Survey. Public Health Rep.\u20082003;118(2):134\u2013143","DOI":"10.1093\/phr\/118.2.134"},{"key":"2021120905433429500_R21","unstructured":"Staat MA, Roberts N, Bernstein DI. Epidemiology and clinical features of intussusception in children &lt;24 months of age in Hamilton County, Ohio [abstract]. Pediatr Res.\u20082001;49(5):242A"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/6\/1206\/1123420\/zpe00608001206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/6\/1206\/1123420\/zpe00608001206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T23:24:17Z","timestamp":1639092257000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/6\/1206\/72702\/Postlicensure-Monitoring-of-Intussusception-After"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,6,1]]},"published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-3793","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,1]]}}}